

## **Product datasheet for TL303318**

## 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com

OriGene Technologies, Inc.

techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## MC3R Human shRNA Plasmid Kit (Locus ID 4159)

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** MC3R Human shRNA Plasmid Kit (Locus ID 4159)

**Locus ID:** 4159

Synonyms: BMIQ9; MC3; MC3-R; OB20; OQTL

**Vector:** pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Selection:

Puromycin

Format: Lentiviral plasmids

Components: MC3R - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 4159).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 019888, NM 019888.1, NM 019888.2, NM 019888.3, BC069105, BC069591, BC069599,

BC096702, BC096737, BC098169, BC098351

UniProt ID: P41968

**Summary:** This gene encodes a G-protein-coupled receptor for melanocyte-stimulating hormone and

adrenocorticotropic hormone that is expressed in tissues other than the adrenal cortex and melanocytes. This gene maps to the same region as the locus for benign neonatal epilepsy.

Mice deficient for this gene have increased fat mass despite decreased food intake,

suggesting a role for this gene product in the regulation of energy homeostasis. Mutations in this gene are associated with a susceptibility to obesity in humans. [provided by RefSeq, Jul

20081

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).